SCM
DAWN

Sterling Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Sterling Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.5K Sell
2,493
-1,950
-44% -$27.5K ﹤0.01% 1610
2025
Q4 		$41.4K Sell
4,443
-283
-6% -$2.36K ﹤0.01% 1868
2025
Q3 		$33.3K Buy
4,726
+2,871
+155% +$19.8K ﹤0.01% 1914
2025
Q2 		$12.1K Buy
1,855
+1,708
+1,162% +$11.7K ﹤0.01% 2011
2025
Q1 		$1.17K Sell
147
-86
-37% -$926 ﹤0.01% 2763
2024
Q4 		$2.95K Buy
233
+168
+258% +$2.34K ﹤0.01% 2655
2024
Q3 		$905 Buy
+65
New +$927 ﹤0.01% 2583

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Sterling Capital Management's DAWN Position: Q1 2026 in Review

Sterling Capital Management reduced its Day One Biopharmaceuticals (DAWN) stake by 44% in Q1 2026, selling an estimated $27.5K and leaving 2,493 shares worth $53.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1610.

Sterling Capital Management first reported a position in DAWN in Q3 2024 and has held it in 7 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Sterling Capital Management held 2,493 shares of Day One Biopharmaceuticals worth $53.5K as of Q1 2026.
  • Sterling Capital Management sold 1,950 Day One Biopharmaceuticals shares in Q1 2026, an estimated $27.5K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1610 holding.
  • Sterling Capital Management first reported a position in Day One Biopharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.